title: Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase- lowering effects of garlic in patients with type 2 diabetes mellitus with obesity.
abstract: BACKGROUND
  Type 2 diabetes mellitus is a chronic disorder characterized by chronic hyperglycemia, with long term macrovascular and microvascular complications. The treatment is lifestyle management, exercise, weight control, and antihyperglycemic drugs such as sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinide. Recently, a direct association between high levels of C-reactive protein and serum adenosine deaminase levels in patients with uncontrolled diabetes with long-term complications has been seen. This study was conducted to assess the antihyperglycemic, lipid-lowering, anti-inflammatory, and improving glycemic control of garlic in type 2 diabetes patients with obesity.
  
  
  METHODS
  This was an open-label, prospective, comparative study, conducted on 60 patients having type 2 diabetes mellitus and obesity. The patients were divided into two groups of 30 each, of either sex. Group 1 was given metformin tablets, 500 mg twice a day (BD)/three times a day (TDS), after meals, and group 2 was given metformin tablets, 500 mg BD/TDS, after meals, along with garlic (Allium sativum) capsules, 250 mg BD. Patients were routinely investigated for fasting and postprandial blood glucose, glycosylated hemoglobin (HbA(1c)), serum adenosine deaminase levels and lipid profile (serum cholesterol, high-density lipoprotein cholesterol, triglycerides and low-density lipoprotein cholesterol) at the start of the study. Patients were followed up for 12 weeks, with monitoring of fasting and postprandial blood glucose at 2 week intervals, and monitoring of the other parameters at the end of study. Data obtained at the end of the study was statistically analyzed using Student's t test.
  
  
  RESULTS
  It was observed that both metformin alone and metformin with garlic reduced fasting blood glucose and postprandial blood glucose significantly, with a greater percentage reduction with metformin plus garlic; however, change in HbA(1c) levels was not significant. A fall in total cholesterol, triglyceride, and low-density lipoprotein and an increase in high-density lipoprotein were more pronounced in patients treated with metformin plus garlic. Similarly, a fall in C-reactive protein and adenosine deaminase levels was greater in patients taking metformin with garlic than in patients taking only metformin.
  
  
  CONCLUSIONS
  Garlic has been shown to have antihyperglycemic and lipid-lowering properties. The additional lowering of C-reactive protein and serum adenosine deaminase levels with garlic suggests that garlic can be a valuable agent in providing good glycemic control and the prevention of long-term complications.
authors: Department of Pharmacology.
authors: Rahat
authors: R
authors: Kumar
authors: Simran
authors: S
authors: Chhatwal
authors: Sahiba
authors: S
authors: Arora
authors: Sita
authors: S
authors: Sharma
authors: Jaswinder
authors: J
authors: Singh
authors: Narinder
authors: N
authors: Singh
authors: Vikram
authors: V
authors: Bhandari
authors: Ashok
authors: A
authors: Khurana
keywords: Allium sativum; C-reactive protein; metformin
references: World Health Organ Tech Rep Ser. 1980;646:1-80
references: 6771926
references: Med Res Rev. 1996 Jan;16(1):111-24
references: 8788216
references: Diabetes. 2005 May;54(5):1566-72
references: 15855347
references: Acta Medica (Hradec Kralove). 2004;47(1):33-5
references: 15168879
references: BMJ. 1996 Apr 27;312(7038):1061-5
references: 8616412
references: Phytother Res. 2005 Apr;19(4):314-9
references: 16041725
references: Clinics (Sao Paulo). 2009 May;64(5):415-20
references: 19488607
references: Arch Intern Med. 1972 Dec;130(6):833-43
references: 5082462
references: JAMA. 2009 Sep 16;302(11):1186-94
references: 19755697
references: Acta Diabetol. 2012 Aug;49(4):307-14
references: 22116350
references: J Clin Endocrinol Metab. 2004 Aug;89(8):3943-8
references: 15292331
references: Clin Chem Lab Med. 2002 Jan;40(1):78-89
references: 11916276
references: Diabetes. 2002 Apr;51(4):1157-65
references: 11916939
references: Diabetes Care. 1990 Jan;13(1):1-8
references: 2404714
references: Ann Intern Med. 1999 Aug 17;131(4):281-303
references: 10454950
references: J Clin Pathol. 1969 Mar;22(2):158-61
references: 5776547
references: Diabetes Care. 2011 Jan;34 Suppl 1:S11-61
references: 21193625
references: Diabetes Care. 2009 Sep;32(9):1734-6
references: 19587368
references: N Engl J Med. 1999 Feb 11;340(6):448-54
references: 9971870
references: Acta Diabetol. 2008 Mar;45(1):1-6
references: 17823766
references: N Engl J Med. 1995 Aug 31;333(9):550-4
references: 7623903
references: Lipids. 1994 Mar;29(3):189-93
references: 8170288
references: Clin Chem. 1974 Apr;20(4):470-5
references: 4818200
references: Pharmazie. 1995 May;50(5):359-61
references: 7604070
references: J Intern Med. 2004 Jul;256(1):1-14
references: 15189360
references: J Lipid Res. 1970 Nov;11(6):583-95
references: 4100998
references: J Nutr. 2001 Mar;131(3s):1020S-6S
references: 11238809
references: Diabetes. 2003 Jul;52(7):1799-805
references: 12829649
references: BMJ. 2000 Aug 12;321(7258):405-12
references: 10938048
references: J Cardiovasc Pharmacol Ther. 2005 Mar;10(1):45-54
references: 15821838
references: Diabetes Care. 1998 May;21(5):701-5
references: 9589227
references: J Cardiovasc Dis Res. 2012 Jul;3(3):185-90
references: 22923934
references: N Engl J Med. 1995 Aug 31;333(9):541-9
references: 7623902
references: J Clin Invest. 2003 Dec;112(12):1796-808
references: 14679176